Did you know we have trillions of bacteria, yeast, and virus cells living within us?  How does this "microbiome" affect our health and well-being? 
Today we spoke about the microbiome with Dr. Elran Haber, who is the CEO of Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases, with a specific focus on immuno-oncology and GI related disorders. Their company is composed of an A-Team of brilliant scientists from Israel and from around the world. Elran and I spoke about the microbiome at large, what it is, why it’s a fascinating new frontier of research, and how we can apply this new knowledge in our own lives to improve our health and longevity. We got to hear about the exciting new interventions that Biomica are developing, as well as other success stories that have been popping up in the field. It’s amazing to think that there’s an entire ecosystem living within us, and that our body and that ecosystem are in constant dialogue and are constantly affecting each other. What’s particularly cool about this new discovery is that it gives us a new framework through which we can judge whether something will be beneficial to our health or not. For instance, maybe we eat something that has a lot of vitamins and low calories, so we think it’s good for us - but if it messes with our microbiome, we’re going to have a problem. Now that's only one way in which this field is creating an entire shift of how we look at health, disease, and treatments. 

Dr. Haber serves as Biomica’s Chief Executive Officer. Prior to joining Biomica, he served as Therapix Biosciences (Nasdaq, TASE: TRPX) CEO leading the company to a successful IPO on Nasdaq and advancing the Company's programs to clinical stage. He spent more than 10 years as Chairman and board member of several privately held, and publicly traded companies. He’s served in senior executive roles in various life science companies and a private investment firm. Dr. Haber holds a PhD in Pharmaceutical Science and an MBA in Finance & Financial Engineering, both from The Hebrew University of Jerusalem, Israel.